Clinical Trial Update: Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating NCX4016 for improving walking distance in peripheral arterial occlusive disease has completed. The study addressed patients with inte…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermittent Claudication
• Peripheral Arterial Occlusive Disease

Drugs mentioned

• NCX4016 (NCX4016)

Snippet

Sponsor: NicOx Research Institute S.r.l. | Conditions: Intermittent Claudication | Phase 2 | Status: COMPLETED